Delving into the Latest Updates on Hongliang (Shanghai) Biomedical Technology Co., Ltd. with Synapse

Overview

Tags

Endocrinology and Metabolic Disease

Digestive System Disorders

Neoplasms

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Endocrinology and Metabolic Disease	1
Neoplasms	1

Top 5 Drug Type	Count

Small molecule drug	1

主要目的：？评价HLN601治疗晚期实体瘤患者的安全性和耐受性，并确定其剂量限制性毒性（DLT）、最大耐受剂量（MTD）/最大给药剂量（MAD）及II期临床推荐剂量（RP2D）。次要目的：？评价HLN601在晚期实体瘤患者中的药代动力学（PK）特征，并获取药代动力学参数。？评价HLN601的初步抗肿瘤活性，为后续临床试验推荐剂量和给药方案提供依据。探索目的： UGT1A1基因多态性与安全性关系、耐受性关系。

[Translation]

Main purpose: ? To evaluate the safety and tolerability of HLN601 in the treatment of patients with advanced solid tumors, and to determine its dose-limiting toxicity (DLT), maximum tolerated dose (MTD)/maximum administered dose (MAD) and phase II clinical recommended dose (RP2D). Secondary purpose: ? To evaluate the pharmacokinetic (PK) characteristics of HLN601 in patients with advanced solid tumors and obtain pharmacokinetic parameters. ? To evaluate the preliminary anti-tumor activity of HLN601 and provide a basis for the recommended dose and dosing regimen for subsequent clinical trials. Exploration purpose: Relationship between UGT1A1 gene polymorphism and safety and tolerability.

Start Date-

Sponsor / Collaborator

Yantai Institute of Materia Medica

[+3]

100 Clinical Results associated with Hongliang (Shanghai) Biomedical Technology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Hongliang (Shanghai) Biomedical Technology Co., Ltd.

Login to view more data

100 Deals associated with Hongliang (Shanghai) Biomedical Technology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Hongliang (Shanghai) Biomedical Technology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 31 Jan 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

1

Login to view more data